Immune Checkpoint Inhibitors: An Innovation in Immunotherapy for the Treatment and Management of Patients with Cancer
Explore this paper's citation graph
Summary
The mechanisms of action, side effects, and patient and family management and education concerns are discussed to provide oncology nurses up-to-date information relevant to caring for cancer-affected patients treated with immune checkpoint inhibitors.
- Type
- review
- Published
- 2017-04-01
- Cited by
- 181
- References
- 39
- Access
- Open access
- OpenAlex
- https://openalex.org/W2607144338
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:1038364
Keywords
Immunotherapy, Cancer immunotherapy, Medicine, Melanoma, Cancer
References
- The origins of cancer robustness and evolvability.
- Evolving synergistic combinations of targeted immunotherapies to combat cancer
- Primer on immuno-oncology and immune response.
- New checkpoint inhibitors ride the immunotherapy tsunami
- Oncology meets immunology: the cancer-immunity cycle.
- Cancer immunotherapy comes of age
- Cancer immunotherapy via dendritic cells
- Clinical Impact of Checkpoint Inhibitors as Novel Cancer Therapies
- Pseudoprogression and Immune-Related Response in Solid Tumors.
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
- Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
- Disparities by race, age, and sex in the improvement of survival for major cancers: Results from the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) program in United States, 1990 to 2010
- Hallmarks of cancer: the next generation.
- Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
- Type I interferon is selectively required by dendritic cells for immune rejection of tumors
- Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer.
- Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells
- Ipilimumab and its toxicities: a multidisciplinary approach.
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Cited by
- Nano‐pulse stimulation induces potent immune responses, eradicating local breast cancer while reducing distant metastases
- The coexpression of multi-immune inhibitory receptors on T lymphocytes in primary non-small-cell lung cancer
- Current management of advanced bladder cancer
- Therapeutic vaccines for high-risk HPV-associated diseases
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- Data-Driven Methods for Advancing Precision Oncology
- Recent Developments in Oncology Immunotherapy, Adverse Effects Part 2
- Guillain–Barré‐like syndrome during pembrolizumab treatment
- Next generation of immune checkpoint therapy in cancer: new developments and challenges
- Development of mRNA vaccines and their prophylactic and therapeutic applications
- Characterization of cancer genomic heterogeneity by next-generation sequencing advances precision medicine in cancer treatment
- How TCR signal strength controls CTL polarisation for target killing
- A mathematical cancer model with BCG immunotherapy combined with immune checkpoints inhibitors: An optimal control approach
- A Comprehensive Review on the Role of Co-signaling Receptors and Treg Homeostasis in Autoimmunity and Tumor Immunity
- How should we diagnose and manage checkpoint inhibitor-associated colitis?
- Addressing New Diagnostic and Treatment Challenges Associated With a New Age of Cancer Treatment
- Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A review update of Patent Literature.
- A review and validation of overall survival extrapolation in health technology assessments of cancer immunotherapy by the National Institute for Health and Care Excellence: how did the initial best estimate compare to trial data subsequently made available?
- Oncolytic adenovirus: A tool for cancer therapy in combination with other therapeutic approaches
- Analysis of Vipadenant and Its In Vitro and In Vivo Metabolites via Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometry
Related papers
- Cancer Immunotherapy and Application of Nanoparticles in Cancers Immunotherapy as the Delivery of Immunotherapeutic Agents and as the Immunomodulators
- B7-H3/CD276: An Emerging Cancer Immunotherapy
- pH-Responsive Nanoparticles for Cancer Immunotherapy: A Brief Review
- New opportunities for nanoparticles in cancer immunotherapy
- Triggering Immune System With Nanomaterials for Cancer Immunotherapy
- Nanotechnology in the arena of cancer immunotherapy
- Drug Delivery Strategies Based on Nanotechnology for Cancer Immunotherapy
- Nanotechnology Approaches to Improving Cancer Immunotherapy
- Polymeric Nanosystems for Immunogenic Cell Death-Based Cancer Immunotherapy.